

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 May 2008 (02.05.2008)

PCT

(10) International Publication Number
WO 2008/049806 A1

(51) International Patent Classification:

C07D 211/58 (2006.01) *C07D 401/14* (2006.01)
C07D 241/20 (2006.01) *A61K 31/495* (2006.01)
C07D 295/10 (2006.01) *A61K 31/445* (2006.01)
C07D 401/12 (2006.01) *A61P 3/00* (2006.01)

[BE/BE]; Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **BERTHELOT, Didier Jean-Claude** [FR/BE]; Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **BUSSCHER, Guuske Frederike** [NL/BE]; Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE).

(21) International Application Number:

PCT/EP2007/061286

(74) Common Representative: **JANSSEN PHARMACEUTICA NV**; Turnhoutseweg 30, B-2340 Beerse (BE).

(22) International Filing Date: 22 October 2007 (22.10.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

06122817.7 24 October 2006 (24.10.2006) EP

(71) Applicant (for all designated States except US): **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MEERPOEL, Lieven** [BE/BE]; Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **LINDERS, Joannes Theodorus Maria** [NL/NL]; Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **JAROSKOVA, Libuse** [CZ/BE]; Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **VIELLEVOYE, Marcel** [NL/NL]; Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **BACKX, Leo Jacobus Jozef**


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(54) Title: PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS



(57) Abstract: The present invention is concerned with novel piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid derivatives having apoB secretion/MTP inhibiting activity and concomitant lipid lowering activity. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of atherosclerosis, pancreatitis, obesity, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and type II diabetes.